Month: February 2021

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer.“We welcome Andy Hurley as we transition into a commercial stage company with a robust research and clinical pipeline,” said Garo Armen, PhD, Chairman and CEO of Agenus. “Andy’s experience and passion in successfully commercializing biopharmaceutical agents and his excitement about our portfolio made him a natural fit to join our team.”“I am excited to join Agenus, one of the true pioneers in immuno-oncology, to lead the efforts for its first potential commercial product launch and to help...

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended December 31, 2020.FINANCIAL RESULTS(1)   Including our Preferred Stock as equity.CASH COMMON SHAREHOLDER DISTRIBUTION DECLARATIONProspect is declaring distributions to common shareholders as follows:These monthly cash distributions represent the 42nd, 43rd, and 44th consecutive $0.06 per share distributions to common shareholders.Prospect expects to declare May, June, July, and August 2021 distributions to common shareholders in May 2021.Based on the declarations above, Prospect’s closing stock price of $6.72 at February 8, 2021 delivers to our common shareholders an annualized distribution yield of 10.7%.Taking into account past distributions and our current...

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be sold by Oncorus. In addition, Oncorus intends to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering price has not yet been determined. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual...

ROANOKE, Va., Feb. 09, 2021 (GLOBE NEWSWIRE) — RGC Resources, Inc. (NASDAQ: RGCO) announced consolidated Company earnings of $4,723,263 or $0.58 per diluted share for the quarter ended December 31, 2020. This compares to consolidated earnings of $4,006,936 or $0.49 per diluted share for the quarter ended December 31, 2019. CEO Paul Nester stated, “We experienced solid earnings growth from improved utility margins associated with infrastructure replacement programs and customer growth as well as lower operating expenses.”Earnings for the twelve months ending December 31, 2020 were $11,280,861 or $1.38 per diluted share compared to $10,271,186 or $1.27 per diluted share for the twelve months ended December 31, 2019. Nester attributed the increase in trailing twelve-month net income to improved utility margins associated with infrastructure...

LINCOLN, Neb., Feb. 09, 2021 (GLOBE NEWSWIRE) — National Research Corporation (NASDAQ:NRC) (the “Company,” “we,” or “our”) today announced 2020 fourth quarter and year-end results.Fourth quarter 2020 compared to the fourth quarter 2019:Net New Sales decreased to $4.6 millionRevenue increased 7% to $34.8 millionOperating Income decreased 15% to $10.2 millionNet Income decreased 6% to $8.2 million2020 calendar year results compared to 2019:Net New Sales increased to $28.1 millionTotal Recurring Contract Value increased 6% to $145.1 millionVoice of the Customer platform recurring contract value grew to $116.4 million, a 19% increaseRevenue increased 4% to $133.3 millionNet Income increased 15% to $37.3 millionWe continue to be inspired by the courageous efforts of our clients to provide care to their patients during the pandemic and...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press releases dated January 20, 2021 and January 21, 2021, the Company has received a receipt for its final short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec, in connection with its previously announced bought deal offering (the “Offering“) for aggregate gross proceeds of $20,000,000 through a syndicate of underwriters led by with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the...

VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is pleased to announce that it has closed the previously announced acquisition to acquire a majority interest (51%) in West Mississauga Medical Ltd. (“West Mississauga Medical”), a comprehensive family medicine and specialist medical clinic with 8 family doctors and 4 specialists serving over 100,000 patients.West Mississauga Medical is a well-established medical clinic located on the border of Brampton, Mississauga and Milton in a high growth area. The clinic has served the community for over 16 years and remained open throughout the COVID-19 pandemic seeing patients via telemedicine...

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS) (“Varonis”) today announced the launch of an underwritten public offering of $400.0 million of shares of its common stock. Varonis expects to grant the underwriters of the offering a 30-day option to purchase up to $60.0 million of additional shares of common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Varonis intends to use the net proceeds from this offering for general corporate purposes, including working capital and capital expenditures, and for potential acquisitions, including complementary businesses, technologies or assets.J.P. Morgan Securities LLC, Barclays Capital Inc., Jefferies LLC and RBC Capital...

TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2020 financial results after market close on Tuesday, March 2, 2021.Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.The call will also be broadcast live and archived on the Company’s website at www.profoundmedical.com under “Webcasts” in the Investors section.About Profound Medical Corp.Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased...